Expertise in
41
conditions

Dr. Rami S. Owera

Hematology
4724 N Davis Hwy, 
Pensacola, FL 
Accepting New Patients
Offers Telehealth
Expertise in
41
conditions
4724 N Davis Hwy, 
Pensacola, FL 

Overview

Rami S. Owera, MD, is an independent hematologist at Ascension Sacred Heart in Pensacola, Florida. Dr. Owera diagnoses and treats blood diseases and blood cancer. Every appointment with Dr. Owera starts with a conversation. He takes the time to answer all your questions - big and small.

Dr. Owera is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Junction Cancer, Anemia, Multiple Myeloma, and Non-Hodgkin Lymphoma.

Dr. Owera is board certified in The American Board Of Internal Medicine - Hematology and The American Board Of Internal Medicine - Medical Oncology. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 15 clinical trials. Dr. Owera is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in AL

Board Certifications

The American Board Of Internal Medicine - Hematology
The American Board Of Internal Medicine - Medical Oncology

Fellowships

University of Missouri Columbia

Hospital Affiliations

Ascension Sacred Heart Hospital Pensacola
Sacred Heart Hospital
D W Mcmillan Memorial Hospital
Hca Florida West Hospital
Baptist Hospital
North Okaloosa Medical Center

Languages Spoken

English
Arabic
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Florida Cancer Specialists & Research Institute, LLC
4724 N Davis Hwy, Pensacola, FL 32503

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2026
Intervention Type: Device
Study Phase: Not Applicable
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Terminated
Publish Date: May 04, 2026
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Dostarlimab, Pembrolizumab, Chemotherapy
Study Phase: Phase 2
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Unknown
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices.
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices.
Journal: JCO precision oncology
Published: April 22, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Jamal Joudeh
Hematology
Expertise in
26
conditions
Dr. Jamal Joudeh
Hematology
Referral may be required

Florida Cancer Specialists & Research Institute, LLC

4724 N Davis Hwy, 
Pensacola, FL 
 (0.1 miles away)
850-696-4000
Languages Spoken:
English, Arabic, Lithuanian
See accepted insurances
Accepting New Patients
Offers Telehealth

Jamal Joudeh, MD, is an independent hematologist at Ascension Sacred Heart in Pensacola, Florida. Dr. Joudeh diagnoses and treats blood diseases and blood cancer. Every appointment with Dr. Joudeh starts with a conversation. He takes the time to answer all your questions - big and small. Dr. Joudeh is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Anemia. Dr. Joudeh is board certified in The American Board Of Internal Medicine - Hematology and The American Board Of Internal Medicine - Medical Oncology. Dr. Joudeh is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Florida Cancer Specialists & Research Institute, LLC

4724 N Davis Hwy, 
Pensacola, FL 
 (0.1 miles away)
850-696-4000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael J. Poiesz, MD, is an independent hematologist at Ascension Sacred Heart in Pensacola, Florida. Dr. Poiesz diagnoses and treats blood diseases and blood cancer. Every appointment with Dr. Poiesz starts with a conversation. He takes the time to answer all your questions - big and small. Dr. Poiesz is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Anemia, Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Thrombocytopenia. Dr. Poiesz is board certified in The American Board Of Internal Medicine - Hematology and The American Board Of Internal Medicine - Medical Oncology. Dr. Poiesz is currently accepting new patients.

Expertise in
5
conditions
Expertise in
5
conditions
Referral may be required

Ascension Sacred Heart Pensacola

5151 N 9th Ave, 
Pensacola, FL 
 (1.0 miles away)
850-416-7780
Languages Spoken:
English, Vietnamese
See accepted insurances
Accepting New Patients

Chi Nguyen is a Hematologist practicing medicine in Pensacola, Florida. Dr. Nguyen is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Pseudocholinesterase Deficiency, GTP Cyclohydrolase 1 Deficiency, Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration. Dr. Nguyen is currently accepting new patients.

Frequently Asked Questions about Dr. Rami S. Owera

How do I make an appointment with Dr. Rami S. Owera?

You can book an appointment with Dr. Rami S. Owera by calling their office at 850-696-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rami S. Owera a top-rated expert for Gastroesophageal Junction Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rami S. Owera is classified as an Distinguished expert for Gastroesophageal Junction Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rami S. Owera specialize in?

While Dr. Rami S. Owera is a Hematology, they have specific expertise in Gastroesophageal Junction Cancer, Anemia, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rami S. Owera participate in research or clinical trials?

Yes. Dr. Rami S. Owera has published 3 articles and abstracts on conditions like Gastroesophageal Junction Cancer. You can view a list of Dr. Rami S. Owera's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rami S. Owera accept my insurance?

Dr. Rami S. Owera accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 850-696-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Owera's expertise for a condition
ConditionClose
    View All 37 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile